Clinical improvement of photophobia with galcanezumab in episodic and chronic migraine - Takeaways - MDSpire

Clinical improvement of photophobia with galcanezumab in episodic and chronic migraine

  • By

  • Elif Ilgaz Aydınlar

  • Pınar Yalınay Dikmen

  • Aysenur Sahin

  • Kerem Birısık

  • June 1, 2026

  • 0 min

Share

  • 1

    The study evaluated photophobia changes in patients with episodic and chronic migraine treated with galcanezumab.

  • 2

    A total of 77 patients participated, with 47 completing the study and showing significant reductions in monthly headache days.

  • 3

    UPSIS-12 scores declined significantly, indicating improvement in photophobia symptoms among responders to galcanezumab.

  • 4

    Responders exhibited notable reductions in ictal photophobia, while interictal sensory symptoms remained largely unchanged.

  • 5

    Galcanezumab treatment was well tolerated, with no serious adverse events reported during the study period.

Original Source(s)

Clinical improvement of photophobia with galcanezumab in episodic and chronic migraine

  • by Elif Ilgaz Aydınlar, Pınar Yalınay Dikmen, Aysenur Sahin, Kerem Birısık

  • June 1, 2026

Related Content

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

Migraine, comorbidity, and risks of severe maternal and neonatal morbidity or mortality: a population-based cohort study

Cognitive Impairment Associated with Mild to Moderate Migraine Episodes: Possible Effects on Workplace Attendance